Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
02 août 2022 16h05 HE
|
Sarepta Therapeutics, Inc.
- Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2022 totaled $233.5 million - Net product revenues for the second quarter 2022 totaled...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 juil. 2022 18h25 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 29, 2022 that...
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
29 juil. 2022 07h00 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced its intent to submit a...
Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
26 juil. 2022 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2022 financial...
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies
06 juil. 2022 08h15 HE
|
Sarepta Therapeutics, Inc.
Sarepta and its partner Roche present new results and analyses at the International Congress on Neuromuscular Diseases (ICNMD), which demonstrate that SRP-9001 shows consistent, statistically...
Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET
05 juil. 2022 16h01 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6,...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 juin 2022 18h15 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2022 that...
Sarepta Therapeutics Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
23 juin 2022 16h01 HE
|
Sarepta Therapeutics, Inc.
- Sarepta to host conference call at 4:15 p.m. Eastern time CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine...
Sarepta Therapeutics Appoints Michael Chambers and Kathryn Boor, Ph.D., to Its Board of Directors
02 juin 2022 16h05 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointments of Michael...
Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
02 juin 2022 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...